TSX runs higher on rate cut expectations
LONDON - N4 Pharma PLC, a pharmaceutical company, has experienced a significant shift in its shareholder structure, as announced on April 23, 2025. Nigel James Theobald, previously holding a 4.30% stake in the company, has seen his share of voting rights decrease to 2.04%.
This change occurred on the same day, following a placement that increased the company’s issued share capital, as previously disclosed on June 7. Theobald’s direct voting rights in N4 Pharma PLC now correspond to 16,981,319 shares, according to the regulatory filing with the London Stock Exchange (LON:LSEG).
The notification, a standard TR-1 form for major holdings, indicates that Theobald does not control any other undertakings that hold an interest in N4 Pharma PLC, nor is he controlled by any other natural person or legal entity in relation to these holdings.
The total number of voting rights in the company now stands at 832,280,349. The filing did not indicate any acquisition or disposal of financial instruments that could affect the percentage of voting rights.
N4 Pharma PLC specializes in the development and commercialization of novel pharmaceutical formulations. The company’s shares are traded on the London Stock Exchange, and this latest development may be of interest to investors and market watchers.
The information for this report is based on a press release statement distributed by RNS, the news service of the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.